UBS Keeps "Buy" Rating on InnoCare Pharma with HK$21.80 Target Price

Deep News

09/27

UBS has released a research report maintaining its "Buy" rating and HK$21.80 target price for InnoCare Pharma (09969).

InnoCare Pharma has entered into a collaboration with Eli Lilly (LLY.US) to discover and develop up to five innovative target projects. The investment bank views this positively, considering it a recognition of the company's research and development capabilities.

The bank noted that the upfront payment and near-term milestone payments total US$100 million, with potential development and commercial milestone payments reaching US$3.25 billion, along with tiered royalties in the single-digit percentage range on net sales.

According to management, all projects will begin from the drug discovery stage. The related payments could bring upside potential to revenue and net profit in 2026.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1191016793"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191016793\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191016793?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-27 12:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191016793","market":"sg","top_or_hot":-1,"title":"UBS Keeps \"Buy\" Rating on InnoCare Pharma with HK$21.80 Target Price","media":"Deep News","content":"<p>UBS has released a research report maintaining its \"Buy\" rating and HK$21.80 target price for <b>InnoCare Pharma (09969)</b>.<br><br>InnoCare Pharma has entered into a collaboration with <b>Eli Lilly (LLY.US)</b> to discover and develop up to five innovative target projects. The investment bank views this positively, considering it a recognition of the company's research and development capabilities.<br><br>The bank noted that the upfront payment and near-term milestone payments total US$100 million, with potential development and commercial milestone payments reaching US$3.25 billion, along with tiered royalties in the single-digit percentage range on net sales.<br><br>According to management, all projects will begin from the drug discovery stage. The related payments could bring upside potential to revenue and net profit in 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS Keeps \"Buy\" Rating on InnoCare Pharma with HK$21.80 Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS Keeps \"Buy\" Rating on InnoCare Pharma with HK$21.80 Target Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-09-27 12:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UBS has released a research report maintaining its \"Buy\" rating and HK$21.80 target price for <b>InnoCare Pharma (09969)</b>.<br><br>InnoCare Pharma has entered into a collaboration with <b>Eli Lilly (LLY.US)</b> to discover and develop up to five innovative target projects. The investment bank views this positively, considering it a recognition of the company's research and development capabilities.<br><br>The bank noted that the upfront payment and near-term milestone payments total US$100 million, with potential development and commercial milestone payments reaching US$3.25 billion, along with tiered royalties in the single-digit percentage range on net sales.<br><br>According to management, all projects will begin from the drug discovery stage. The related payments could bring upside potential to revenue and net profit in 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1191016793","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191016793","pubTimestamp":1790483430,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"UBS has released a research report maintaining its \"Buy\" rating and HK$21.80 target price for InnoCare Pharma (09969).InnoCare Pharma has entered into a collaboration with Eli Lilly (LLY.US) to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK1574":"生物医药B类股","09969":"诺诚健华","BK0239":"医药制造","EWH":"香港ETF-iShares MSCI","BK1161":"生物科技"},"translate_title":"瑞银维持诺诚健华“买入”评级，目标价21.80港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"EWH":1,"09969":1},"content_text":"UBS has released a research report maintaining its \"Buy\" rating and HK$21.80 target price for InnoCare Pharma (09969).InnoCare Pharma has entered into a collaboration with Eli Lilly (LLY.US) to discover and develop up to five innovative target projects. The investment bank views this positively, considering it a recognition of the company's research and development capabilities.The bank noted that the upfront payment and near-term milestone payments total US$100 million, with potential development and commercial milestone payments reaching US$3.25 billion, along with tiered royalties in the single-digit percentage range on net sales.According to management, all projects will begin from the drug discovery stage. The related payments could bring upside potential to revenue and net profit in 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}